272,517 Shares in NeoGenomics, Inc. (NASDAQ:NEO) Bought by Point72 Asset Management L.P.

Point72 Asset Management L.P. bought a new position in NeoGenomics, Inc. (NASDAQ:NEO) during the 2nd quarter, Holdings Channel reports. The fund bought 272,517 shares of the medical research company’s stock, valued at approximately $5,979,000.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. LPL Financial LLC increased its holdings in shares of NeoGenomics by 2.4% during the 2nd quarter. LPL Financial LLC now owns 19,250 shares of the medical research company’s stock worth $422,000 after purchasing an additional 455 shares during the period. Yorktown Management & Research Co Inc increased its holdings in shares of NeoGenomics by 4.6% during the 2nd quarter. Yorktown Management & Research Co Inc now owns 18,300 shares of the medical research company’s stock worth $402,000 after purchasing an additional 800 shares during the period. Commonwealth Equity Services LLC increased its holdings in shares of NeoGenomics by 3.8% during the 2nd quarter. Commonwealth Equity Services LLC now owns 25,647 shares of the medical research company’s stock worth $562,000 after purchasing an additional 945 shares during the period. Summit Creek Advisors LLC increased its holdings in shares of NeoGenomics by 0.3% during the 2nd quarter. Summit Creek Advisors LLC now owns 348,208 shares of the medical research company’s stock worth $7,640,000 after purchasing an additional 960 shares during the period. Finally, LS Investment Advisors LLC increased its holdings in shares of NeoGenomics by 18.5% during the 2nd quarter. LS Investment Advisors LLC now owns 10,897 shares of the medical research company’s stock worth $239,000 after purchasing an additional 1,701 shares during the period. Hedge funds and other institutional investors own 84.84% of the company’s stock.

Several research analysts have recently issued reports on the stock. Benchmark set a $27.00 price objective on shares of NeoGenomics and gave the stock a “buy” rating in a report on Wednesday, July 31st. ValuEngine lowered shares of NeoGenomics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, August 1st. Raymond James lifted their target price on shares of NeoGenomics from $23.00 to $27.00 and gave the company an “outperform” rating in a research report on Wednesday, July 31st. Needham & Company LLC set a $27.00 target price on shares of NeoGenomics and gave the company a “buy” rating in a research report on Wednesday, July 31st. Finally, Zacks Investment Research lowered shares of NeoGenomics from a “buy” rating to a “hold” rating in a research report on Thursday, July 25th. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $24.75.



In other NeoGenomics news, Director Steven C. Jones sold 1,691 shares of the business’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $25.00, for a total value of $42,275.00. Following the transaction, the director now directly owns 245,234 shares in the company, valued at $6,130,850. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Steven C. Jones sold 181,339 shares of the business’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $24.92, for a total transaction of $4,518,967.88. Following the completion of the transaction, the director now owns 245,234 shares in the company, valued at $6,111,231.28. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 241,370 shares of company stock worth $6,017,680. 8.80% of the stock is owned by company insiders.

Shares of NeoGenomics stock traded down $0.78 during trading on Tuesday, hitting $20.79. 40,297 shares of the company’s stock traded hands, compared to its average volume of 873,884. The company has a debt-to-equity ratio of 0.25, a current ratio of 4.67 and a quick ratio of 4.52. The firm’s fifty day moving average price is $24.12 and its 200 day moving average price is $22.40. NeoGenomics, Inc. has a twelve month low of $11.05 and a twelve month high of $26.89. The company has a market cap of $2.24 billion, a PE ratio of 160.08 and a beta of 0.97.

NeoGenomics (NASDAQ:NEO) last issued its earnings results on Tuesday, July 30th. The medical research company reported $0.07 earnings per share for the quarter, beating the consensus estimate of $0.05 by $0.02. NeoGenomics had a net margin of 0.57% and a return on equity of 4.97%. The business had revenue of $101.71 million for the quarter, compared to analyst estimates of $97.32 million. During the same period in the previous year, the business earned $0.05 EPS. The firm’s revenue was up 50.1% on a year-over-year basis. As a group, equities research analysts anticipate that NeoGenomics, Inc. will post 0.19 earnings per share for the current year.

NeoGenomics Profile

NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.

Further Reading: Preferred Stock

Want to see what other hedge funds are holding NEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NeoGenomics, Inc. (NASDAQ:NEO).

Institutional Ownership by Quarter for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.